PE09492006A1 - Fused pyrazole derivatives as receptor agonists Niacin - Google Patents

Fused pyrazole derivatives as receptor agonists Niacin

Info

Publication number
PE09492006A1
PE09492006A1 PE0014722005A PE0014722005A PE09492006A1 PE 09492006 A1 PE09492006 A1 PE 09492006A1 PE 0014722005 A PE0014722005 A PE 0014722005A PE 0014722005 A PE0014722005 A PE 0014722005A PE 09492006 A1 PE09492006 A1 PE 09492006A1
Authority
PE
Peru
Prior art keywords
c6
c1
cyclopropa
tetrahydro
c2
Prior art date
Application number
PE0014722005A
Other languages
Spanish (es)
Inventor
P Douglas Boatman
Thomas O Schrader
Philip J Skinner
Jae-Kyu Jung
Graeme Semple
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US63866804P priority Critical
Priority to US67652105P priority
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of PE09492006A1 publication Critical patent/PE09492006A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring-systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE PIRAZOL DE FORMULA Ia, DONDE X ES NYZ ES CR7, OX ES CR7 YZ ES N; REFERRED TO COMPOUNDS pyrazole derivatives of formula Ia, wherein X is CR7 NYZ ES, ES CR7 OX YZ is N; R1 Y R4 SON H, ACILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R1 and R4 are H, C1-C6 acyl, C2-C6, among others; R2 Y R3 SON H, ACILO C1-C6, ALQUENILO C2-C6, ALQUILO C1-C6, ENTRE OTROS; R2 and R3 are H, C1-C6 acyl, C2-C6 alkenyl, C1-C6 alkyl, among others; R5 Y R6 SON H, ACILO C1-C6, ALQUENILO C2-C6, ALCOXILO C1-C6, ENTRE OTROS; R5 and R6 are H, C1-C6 acyl, C2-C6 alkenyl, C1-C6, among others; R7 ES CARBOXILO, CARBO-ALCOXILO C1-C6 O TETRAZOL-5-ILO. R7 is carboxyl, CARBO-C1-C6 or tetrazole-5-yl. SON COMPUESTOS PREFERIDOS: ACIDO 3b,4,4a,5-TETRAHIDRO-3H-CICLOPROPA[3,4]CICLOPENTA[1,2-c]PIRAZOL-3-CARBOXILICO, 4-(2H-TETRAZOL-5-IL)-1a,3,5,5a-TETRAHIDRO-1H-2,3-DIAZA-CICLOPROPA[a]PENTALENO, ACIDO 1a,3,5,5a-TETRAHIDRO-1H-2,3-DIAZA-CICLOPROPA[a]PENTALENO-4-CARBOXILICO, ENTRE OTROS. Preferred compounds: ACID 3b, 4,4a, 5-tetrahydro-3H-cyclopropa [3,4] cyclopenta [1,2-c] pyrazol-3-carboxylic acid, 4- (2H-tetrazol-5-yl) -1a , 3,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa [a] pentalene ACID 1a, 3,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa [a] pentalene-4- carboxylic acid, among others. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA YA UN PROCEDIMIENTO DE PREPARACION. ALSO REFERRED TO A pharmaceutical composition and method of preparation. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR RUP25 Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS, INCLUIDAS DISLIPIDEMIAS, ARTEOESCLEROSIS, CARDIOPATIA CORONARIA, RESISTENCIA A LA INSULINA, DIABETES TIPO 2, SINDROME XY SEMEJANTES Such compounds are RUP25 AGONISTS RECEIVER AND ARE USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING dyslipidemia, ARTEOESCLEROSIS, coronary heart disease, insulin resistance, type 2 diabetes, XY LIKE SYNDROME
PE0014722005A 2004-12-23 2005-12-15 Fused pyrazole derivatives as receptor agonists Niacin PE09492006A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US63866804P true 2004-12-23 2004-12-23
US67652105P true 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
PE09492006A1 true PE09492006A1 (en) 2006-10-11

Family

ID=36593187

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0014722005A PE09492006A1 (en) 2004-12-23 2005-12-15 Fused pyrazole derivatives as receptor agonists Niacin

Country Status (24)

Country Link
US (3) US7241792B2 (en)
EP (1) EP1831178A2 (en)
JP (1) JP2008525476A (en)
KR (1) KR20070088808A (en)
CN (2) CN102311378A (en)
AR (1) AR055015A1 (en)
AU (1) AU2005319121A1 (en)
BR (1) BRPI0519262A2 (en)
CA (1) CA2589648A1 (en)
CU (1) CU23691B7 (en)
EA (1) EA013184B1 (en)
GE (1) GEP20105126B (en)
GT (1) GT200500379A (en)
HN (1) HN2005036256A (en)
IL (1) IL183654D0 (en)
MA (1) MA29148B1 (en)
NI (1) NI200700161A (en)
NO (1) NO20073766L (en)
NZ (1) NZ555721A (en)
PA (1) PA8658301A1 (en)
PE (1) PE09492006A1 (en)
TN (1) TNSN07236A1 (en)
TW (1) TW200635904A (en)
WO (1) WO2006069242A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US20070093545A1 (en) * 2003-11-21 2007-04-26 Arena Pharmaceuticals, Inc. 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
PE09492006A1 (en) * 2004-12-23 2006-10-11 Arena Pharm Inc Fused pyrazole derivatives as receptor agonists Niacin
PT1901731E (en) 2005-06-28 2011-05-11 Merck Sharp & Dohme Niacin receptor agonists, compositions containing such compounds and methods of treatment
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2470508A1 (en) * 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AU2012222149B2 (en) 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA201391233A1 (en) 2011-02-25 2014-02-28 Арена Фармасьютикалз, Инк. Crystal forms and methods of obtaining cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105336A (en) * 1961-05-16 1963-10-01 Package Machinery Co Converting wrapping machines to wrap different size articles
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
AT355279T (en) * 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole as modulators of the estrogen receptor
EP1262475A4 (en) 2000-03-09 2005-01-05 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP4279561B2 (en) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド Dihydropyrrolo [1,2-a] indole and tetrahydropyrido [1,2-a] -indole derivatives as prostaglandin D2 receptor antagonists
CN1233648C (en) 2001-06-27 2005-12-28 尔艾斯特公司 Chiral salen catalyst and methods for prepn. of chirol compounds from racemic epoxides by using new catalyst
WO2003022814A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
DE10148617A1 (en) * 2001-09-25 2003-04-24 Schering Ag New 3-acylamino-cyclopentanopyrazole derivatives, useful for treating e.g. cancer and viral infections, inhibit cyclin-dependent kinase
AR038136A1 (en) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles with fluorine substitution compositions containing these compounds and methods of treatment
IL164094D0 (en) 2002-03-19 2005-12-18 Ono Pharmaceutical Co Carboxyoic acid compounds and drugs containing thecompounds as the active ingredient
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20060167270A1 (en) * 2002-10-10 2006-07-27 Arena Pharmaceuticals Inc. 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
AR041089A1 (en) 2003-05-15 2005-05-04 Merck & Co Inc Farmaceutiicas procedure and compositions for treating atherosclerosis, dyslipidemias and related conditions
AU2004260636A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
NZ548496A (en) 2004-02-14 2010-02-26 Smithkline Beecham Corp Medicaments with HM74A receptor activity for disorder of lipid metabolism
PE09492006A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc Fused pyrazole derivatives as receptor agonists Niacin

Also Published As

Publication number Publication date
GEP20105126B (en) 2010-12-10
CN102321024A (en) 2012-01-18
AR055015A1 (en) 2007-08-01
IL183654D0 (en) 2007-09-20
US20090258892A1 (en) 2009-10-15
US7612106B2 (en) 2009-11-03
CA2589648A1 (en) 2006-06-29
PA8658301A1 (en) 2006-10-13
AU2005319121A1 (en) 2006-06-29
CU23691B7 (en) 2011-09-21
JP2008525476A (en) 2008-07-17
CN102311378A (en) 2012-01-11
GT200500379A (en) 2006-10-25
EA013184B1 (en) 2010-02-26
WO2006069242A3 (en) 2006-08-31
EA200701361A1 (en) 2007-12-28
TW200635904A (en) 2006-10-16
US20070073062A1 (en) 2007-03-29
NI200700161A (en) 2008-04-21
NO20073766L (en) 2007-09-21
US20060205955A1 (en) 2006-09-14
KR20070088808A (en) 2007-08-29
NZ555721A (en) 2011-02-25
BRPI0519262A2 (en) 2009-01-06
TNSN07236A1 (en) 2008-11-21
WO2006069242A2 (en) 2006-06-29
CU20070144A7 (en) 2010-01-22
MA29148B1 (en) 2008-01-02
EP1831178A2 (en) 2007-09-12
US7241792B2 (en) 2007-07-10
HN2005036256A (en) 2010-02-08

Similar Documents

Publication Publication Date Title
JP5406716B2 (en) Indole compounds
CN101247853B (en) Substituted indole compounds having NOS inhibitory activity
AU2003257145B2 (en) Substituted furo (2,3-b) pyridine derivatives
CA2527933C (en) Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US7071335B2 (en) 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
CN1950371B (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
US5874437A (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
JP4054368B2 (en) Substituted methylaryl or heteroarylamide compounds
JP5437954B2 (en) Benzazolylpiperazine derivatives having mGluR1- and mGluR5-antagonist activity
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
JP4311770B2 (en) Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] -indol-8-one and its derivatives
KR100849839B1 (en) N-Substituted nonaryl-heterocyclic NMDA/NR2B antagonists and a pharmaceutical composition comprising the same
JP4489354B2 (en) Spiroindene and spiroindane compounds
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
US7514068B2 (en) Biphenyl-pyrazolecarboxamide compounds
ES2262817T3 (en) Beta-3 oxindol 3-substituted agonists.
AU2002311833B2 (en) Spiropyrazole compounds
TWI558710B (en) Phosphoinositide 3-kinase inhibitor has a connection portion of zinc
TWI663161B (en) Trk inhibitor compound
ES2323876T3 (en) Derivatives of 1- (4-piperidinil) -1,3-dihidro-2h-benzoxazol-2-ona and related compounds as analogs of nociceptine and ligands of ent1 for the treatment of pain.
US6864261B2 (en) Therapeutic agents useful for treating pain
JP5539235B2 (en) Amide compounds, compositions and uses thereof
US20090118503A1 (en) Faah inhibitors
JP4865221B2 (en) New compounds and their use
AU2003294313B2 (en) 4-Tetrazolyl-4phenylpiperidine derivatives for treating pain

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed